THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL CANINO KALETA | — |
| BRENDAN DEVINE | — |
| CHRISTOPHER HARTMANN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
Health Issues HCR
Issues related to surprise billing law and regulation. Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. Issues related to removing barriers to biosimilar medicine access. Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program. Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023. Issues related to mental health coverage, workforce, and mental health parity. Behavioral Health Network and Directory Improvement Act. S. 1001, Issues related to the Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 1843, the Telehealth Expansion Act of 2023. H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues relating to S. 464/ H.R. 2630, the Safe Step Act; related amendment to S. 1339, the Pharmacy Benefit Manager Reform Act. H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023. S. 2840, Bipartisan Primary Care and Health Workforce Act and issues related commercial insurance, telehealth, and pharmacy benefits.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDAN DEVINE | — |
| CHRISTOPHER HARTMANN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
Defense DEF
Pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDAN DEVINE | — |
| KATHRYN GALLAGHER | — |
| CHRISTOPHER HARTMANN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
Pharmacy PHA
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL CANINO KALETA | — |
| BRENDAN DEVINE | — |
| KATHRYN GALLAGHER | — |
| CHRISTOPHER HARTMANN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.